Showing 7491-7500 of 7755 results for "".
- Omalizumab Shown to Significantly Improve Chronic Idiopathic Urticaria Symptomshttps://practicaldermatology.com/news/20130227-omalizumab_shown_to_significantly_improve_chronic_idiopathic_urticaria_symptoms/2459605/Results from the recent ASTERIA II trial showed that the biologic agent omalizumab (Novartis) may be effective for patients with moderate to severe chronic idiopathic urticaria (CIU), referred to as chronic spontaneous urticaria (CSU) outside the United States, who remained symptomatic despite treat
- Some Patients Apply Sunscreen to Nevi Onlyhttps://practicaldermatology.com/news/20130225-some_patients_apply_sunscreen_to_nevi_only/2459610/An unexpected number of patients with nevi report that they selectively apply sunscreens to moles only, and almost half of them say that a dermatologist told them to do so, according to a new study. (J Eur Acad Dermatol Venereol. e-pub). Of 1,816 European subjects surveyed (59.3% females, age 14-90
- Epiduo Approved For Patients as Young as 9-Years-Oldhttps://practicaldermatology.com/news/20130219-epiduo_approved_to_treat_acne_in_patients_as_young_as_nine_years_old/2459612/Based on the results of a recent clinical study in pediatric patients, the FDA has approved Epiduo (adapalene 0.1%/BPO 2.5%, Galderma) Gel to treat acne in children as young as nine years old. In the 12-week multicenter, randomized, vehicle-controlled, double-blind study, investigators evaluated the
- Red Alert: Rosacea Awareness Month Highlights Social Impact and Warning Signs of Rosaceahttps://practicaldermatology.com/news/20130215-red_alert_rosacea_awareness_month_highlights_social_impact_and_warning_signs_of_rosacea/2459615/According to a new patient survey conducted by the NRS, most rosacea patients feel the negative social impact of their condition regardless of which rosacea subtype they may have. While 61 percent of those with only subtype 1 (erythematotelangiectatic) ro
- Aqua Pharmaceuticals Announces New VP of Saleshttps://practicaldermatology.com/news/20130212-aqua_pharmaceuticals_announces_new_vp_of_sales/2459617/Aqua Pharmaceuticals recently promoted Ted White to Chief Operating Officer (COO). White moves to the new role from his previous position as Vice President of Sales. As COO, White will be responsible for overseeing the daily operation of Aqua and developing business strategies, serving as second-in-
- Survey Data Highlight Expenses and Access-to-Care for Psoriasis Patientshttps://practicaldermatology.com/news/20130208-survey_data_highlight_expenses_and_access-to-care_for_psoriasis_patients/2459618/New findings from the National Psoriasis Foundation (NPF) indicate that patients with psoriasis and psoriatic arthritis patients spend more than $2,500 per year in out-of-pocket costs for their disease. In an analysis of eight years of data to determine access-to-care issues and out-of-pocket costs
- Merz Aesthetics Appoints New VPhttps://practicaldermatology.com/news/20130206-merz_aesthetics_appoints_new_vp/2459620/Jim Hartman has been appointed Vice President of Merz Aesthetics, Inc. Business Unit, which includes Xeomin, Radiesse, and Belotero Balance. Prior to joining Merz, Hartman was the Vice President, Global Marketing & Business Development, at Obagi Medical Products, a provider of topical skincare treat
- La Roche-Posay Contributes to The Mollie Biggane Melanoma Foundationhttps://practicaldermatology.com/news/20130203-la_roche-posay_contributes_to_the_mollie_biggane_melanoma_foundation/2459621/As part of their continued efforts towards sun safety education and awareness, La Roche-Posay is partnering with Mollie's Fund for the second year in a row. To honor the life of Mollie Biggane – a college sophomore who tragically passed away from melanoma a
- Obagi and Suneva Partner to Distribute Facial Rejuvenation Complexhttps://practicaldermatology.com/news/20130201-obagi_and_suneva_parter_to_distribute_facial_rejuvenation_complex/2459622/Obagi Medical Products and Suneva Medical jointly announced a partnership to co-distribute ReGenica Facial Rejuvenation Complex, a product that accelerates the appearance of post-laser skin through the fusion of stem cells and growth factors. It contains the Multipotent CCM Complex (Cell Conditioned
- La Roche-Posay Launches New Pore-Refining Moisturizerhttps://practicaldermatology.com/news/20130201-la_roche-posay_launches_new_pore-refining_moisturizer/2459623/La Roche-Posay's launched the Effaclar MAT Daily Mattifying + Pore-Refining Moisturizer, a formula that contains a unique combination of ingredients that neutralizes shine for lastingly matte, clear, and balanced skin with tightened pores, according to the company. The product is designed for patien